Attorney Docket No.: 21402-157 (Cura-457)

Express Mail Label No.: EV139501646US Date of Deposit: November 12, 2002.



PPLICANTS:

Grosse, et al.

SERIAL NUMBER:

09/976,782

EXAMINER:

Not Yet Assigned

FILING DATE:

October 12, 2001

ART UNIT:

1645

For:

Novel Proteins and Nucleic Acids Encoding Same

Box IDS

Commissioner for Patents Washington, D.C. 20231

RECEIVED

NOV 1 4 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page) in duplicate;
- 3. Copies of cited references A1, B1-B9 and C54-C57; and
- 4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21402-157 (Cura-457). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted.

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Express Mail Label No.: E 739501646US

Date of Deposit: November 12, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Grosse, et al.

SERIAL NUMBER:

09/976,782

EXAMINER:

Not Yet Assigned

NOV 1 4 2002

FILING DATE:

October 12, 2001

ART UNIT:

1645

TECH CENTER 1600/2900

FOR:

Novel Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Grosse, c. al 09/976,782

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-157.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C. One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1732050v1

Express Mail No. EV139501646US

Date of Deposit: November 12, 2002



NOV 1 4 2002 Page 1 of 3

JC16 30; Please type a plus sign (+) in this box
Under the Pup

TECH CENTER 1600/2900

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	09/976,782
	Filing Date	October 12, 2001
INFORMATION DISCLOSURE	First Named Inventor	Grosse
STATEMENT BY APPLICANT	Group Art Unit	1645
•	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	21402-157

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,403,717	4/4/95	Holmes			12/10/92

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.			Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	EP	0334962	Oriental Yeast Co., Ltd.	10/4/89	Х	
	B2	EP	0879885	Smithkline Beecham Corporation	1/16/98	Х	
	В3	EP	0943685	BASF Aktiengesellschaft	1/22/99		Х
	B4	wo	00/50589	Ludwig Institute for Cancer Research	8/31/00	Х	
	B 5	wo	01/75067	Hyseq, Inc.	10/11/01	X	
	B6	wo	95/02057	The Institute of Cancer Research	1/19/95	Х	
	B7	wo	95/28484	Amgen Inc.	10/26/95	X	
	B8	wo	98/42738	Human Genome Sciences, Inc.	10/1/98	X	
	B9	wo	99/58558	Incyte Pharmaceuticals, Inc.	11/18/99	х	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Exam Initials				
	C54	Drmanac, et al. Accession number: ABG02799 (February 13, 2002).		
	C55	Drmanac, et al. Accession number: ABG28270 (February 18, 2002).		
	C56	Mitchell, et al. Accession number: X78549 (July 19, 1994).		
	C57	International Search Report for PCT US 01/31922, mailed 10/9/02.		

* a copy of	this reference is not provided as it was	previously cited by or submitted to the office in a prior application,
Serial No.	, filed	, and relied upon for an earlier filing date under
35 U.S.C.	120 (continuation, continuation-in-part,	

Examiner Signature	Date Considered	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.